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Abstract 
 
Introduction 
Non-small cell lung cancer (NSCLC) arises when epithelial cells lining the 
bronchial tubes undergo aberrant cell growth due to up-regulation of the 
programmed death ligand (PD-L1). A Marketing Authorisation Application 
for durvalumab was recently submitted to the European Medicines Agency 
for the treatment of patients with stage III, unresectable NSCLC whose dis-
ease did not progress following platinum-based chemotherapy. By inhibiting 
PD-1, durvalumab restores T-cell activation, enabling the effective detection 
and destruction of tumour cells.  
Methodology  
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer. Quality assessment was conducted to assess 
the risk of bias at the study level based on the EUnetHTA internal validity 
for randomized controlled trials. Furthermore, the magnitude of clinically 
meaningful benefit that can be expected from durvalumab was evaluated 
based on, both the original and an adapted version of the Magnitude of Clin-
ical Benefit Scale developed by the European Society for Medical Oncology. 
Results of the PACIFIC trial 
In the phase III, PACIFIC study, 713 patients with stage III, unresectable 
NSCLC, without progression following platinum-based chemotherapy, were 
randomised 2:1 to durvalumab (10 mg/kg IV every 2 weeks) or matching 
placebo for up to 12 months. At a median follow-up of 14.5 months, durval-
umab increased the median progression-free survival (PFS) by 11.2 months, 
compared to placebo, irrespective of PD-L1 expression level prior to chemo-
radiotherapy. Durvalumab also increased the overall response rate (ORR) by 
12.4%, duration of response (DOR) (>13.8 months), time to death or distant 
metastasis (TTDM) by 9 months, and reduced the incidence of new brain 
metastases by 5.5% compared with placebo. Immune-mediated, treatment-
related adverse events (AEs) requiring glucocorticoids or endocrine therapy 
were more commonly reported in the durvalumab group; pneumonitis and 
pneumonia resulted in discontinuation in 6.3% and 1.1% of durvalumab re-
cipients, respectively.  
Conclusion 
Overall, durvalumab increases PFS, ORR, DOR, and TTDM in patients 
with stage III NSCLC, regardless of PD-L1 expression level prior to 
chemoradiation or histology, compared to placebo. However, overall survival 
(OS), quality of life (QoL) and long-term safety data are awaited, and study 
participants may not be representative of those in clinical practice. Direct 
comparison trials are lacking, to other immunotherapies (e.g. 
pembrolizumab), and cross-trial comparisons are cautioned due to 
differences in patient selection based on different PD-L1 assays. Further 
research is needed regarding the duration and timing of immunotherapy, 
the best regimen of chemoradiation for combination, and patient selection 
for greatest benefit based on predictive markers of efficacy and resistance.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is durvalumab? 
A0022 Who manufactures durvalumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has durvalumab received marketing authorisation? 
Health problem and current use 
A0002 What is NSCLC? 
A0004 What is the natural course of NSCLC? 
A0006 What are the consequences of NSCLC for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of NSCLC? 
A0003 What are the known risk factors for NSCLC? 
A0024 How is NSCLC currently diagnosed according to published guidelines and in practice? 
A0025 How is NSCLC currently managed according to published guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of durvalumab on mortality? 
D0005 How does durvalumab affect symptoms and findings (severity, frequency) of NSCLC? 
D0006 How does durvalumab affect progression (or recurrence) of NSCLC? 
D0011 What is the effect of durvalumab on patients ̕ body functions? 
D0012 What is the effect of durvalumab on generic health-related quality of life? 
D0013 What is the effect of durvalumab on disease-specific quality of life? 
Safety 
C0008 How safe is durvalumab in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying durvalumab? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of durvalumab? 
A0021 What is the reimbursement status of durvalumab? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code: 
Durvalumab/Imfinzi™/MEDI4736 
 
B0001: What is durvalumab? 
Up-regulation of the programmed death ligand 1 (PD-L1) in patients with 
tumours increases the propensity for cancer cells to evade immune surveil-
lance. Durvalumab, a monoclonal antibody, is an immune checkpoint inhib-
itor. By blocking PD-L1 from binding to PD-1 and CD80 receptors, durval-
umab restores T-cell activation, enabling the effective detection and destruc-
tion of tumour cells.  
Durvalumab is available in 120 mg/2.4 ml (50 mg/ml) and 500 mg/10 ml (50 
mg/ml) single-use vials. It is administered as an intravenous infusion over 
60 minutes, at a dose of 10 mg/kg, every 2 weeks starting within 6 weeks af-
ter chemoradiotherapy until disease progression or unacceptable toxicity [2].  
During treatment, patients require periodic monitoring for blood glucose, 
thyroid, liver and renal function. Dose interruption or discontinuation may 
be required in patients that develop immune-mediated pneumonitis, hepati-
tis, colitis, nephritis, endocrinopathies, infections, infusion-related reac-
tions, or intolerance due to adverse events (AEs) [2]. 
 
A0022: Who manufactures durvalumab? 
MedImmune LLC, a subsidiary of AstraZeneca 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Durvalumab is indicated for the treatment of patients with stage III non-
small cell lung cancer (NSCLC) after prior chemoradiotherapy [3].  
 
 
 
 
anti-PD-L1 antibody, 
immune checkpoint 
inhibitor 
10 mg/kg IV over 60 
minutes every 2 weeks 
monitor thyroid, liver 
and renal function; 
interrupt/discontinue 
for immune-mediated 
AEs 
stage III NSCLC patients 
previously treated with 
chemoradiotherapy 
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4 Current regulatory status 
A0020: For which indications has durvalumab received marketing authori-
sation? 
In May 2017, the US Food and Drug Administration (FDA) issued acceler-
ated approval of durvalumab for the treatment of patients with locally ad-
vanced or metastatic urothelial carcinoma (MUC) with disease progression 
during or within 12 months of neoadjuvant or adjuvant platinum-based 
chemotherapy. The VENTANA PD-L1 (SP263) Assay (Ventana Medical 
Systems, Inc.) was approved as a complementary diagnostic for assessing 
PD-L1 protein expression. Initial approval was based on the objective re-
sponse rate (ORR) and duration of response (DOR) reported in patients 
with PD-L1-expressing tumours in a single-arm, open-label, phase I/II, 
Study 1108 trial. Continued approval is contingent upon verification 
through confirmatory trials [2, 4]. 
In July 2017, the FDA granted durvalumab breakthrough therapy designa-
tion for the treatment of patients with stage III NSCLC whose disease had 
not progressed following platinum-based chemoradiotherapy [5]. By October 
2017, durvalumab was granted a priority review for a supplemental biologics 
license application based on progression-free survival (PFS) results from the 
phase III PACIFIC trial [6].  
Durvalumab does not currently have marketing authorisation in Europe for 
any indication. However, in October 2017, a Marketing Authorisation Appli-
cation (MAA) for durvalumab was submitted to the European Medicines 
Agency (EMA) for the treatment of patients with stage III, unresectable 
NSCLC whose disease had not progressed following platinum-based chemo-
radiotherapy [7, 8].  
 
 
 
5 Burden of disease 
A0002: What is NSCLC? 
NSCLC is the most common epithelial lung cancer and accounts for approx-
imately 80–85% of all lung cancers. The most common histological types of 
NSCLC are squamous (25–30%), adenocarcinomas (40%) and large cell car-
cinomas (10–15%). Squamous cell, also known as epidermoid, carcinoma is 
typically centrally located, characterized by keratin, more common in males 
and tobacco smokers, and has a 10% survival rate at 5 years [9, 10]. Adeno-
carcinoma and large cell carcinoma are typically peripherally located and 
have survival rates of approximately 5–6% at 5 years. Approximately 7–35% 
of NSCLC patients have driver gene alterations in the epidermal growth fac-
tor receptor (EGFR), anaplastic lymphoma kinase (ALK) or ROS1, while 1–
3% have BRAF mutations. NSCLC tumours express the immune checkpoint 
PD-L1 that negatively regulates T-cell proliferation and induces cell death 
in tumour-specific T-cells. PD-L1 expression ranges from 23–27% in non-
squamous NSCLC and from 19–56% in squamous NSCLC [11].  
FDA: licensed for  
MUC in May 2017 
FDA: priority review for 
stage III NSCLC in 
October 2017 
EMA: MMA for stage III 
NSCLC in October 2017 
NSCLC accounts for 80–
85% of all lung cancers 
 
 
 
 
 
 
 
 
PD-L1 expression in 
NSCLC 
non-squamous: 23–27% 
squamous: 19–56% 
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A0004: What is the natural course of NSCLC? 
Lung cancer typically arises when epithelial cells lining the bronchial tubes 
undergo aberrant cell growth. To facilitate treatment, lung cancer is staged 
from I through IV based on tumour size, and presence or absence of lymph 
node involvement and metastases (TNM). Stage I lung cancer is <3 cm and 
localized to one lobe; stage II has spread to other parts of the lung or lymph 
nodes; stage III may be large or spread to lymph nodes between the lungs; 
and stage IV has metastasized to the adjacent lung, brain, liver or bones [9, 
12] 
 
A0006: What are the consequences of NSCLC for the society? 
Lung cancer is the second most commonly diagnosed cancer. While the im-
plementation of smoking cessation programs and multidisciplinary treat-
ments have reduced the incidence and mortality, 52–58% of lung cancer pa-
tients present with advanced-stage disease when curative treatment is no 
longer feasible. PD-L1 is a poor prognostic factor in NSCLC [13], leading to 
a high rate of relapse and early formation of micro-metastases [14].  
 
A0023: How many people belong to the target population? 
Lung cancer is the leading cause of cancer-related death in men and the sec-
ond in women worldwide. The age standardized incidence rate for the Euro-
pean Standard Population was 56.9 per 100,000 persons per year in 2014. In 
Austria, 2,894 men and 1,822 women were newly diagnosed with lung cancer 
in 2014; and 2,450 men and 1,458 women died due to lung cancer (47.3 per 
100,000 persons per year) [15]. Approximately 6.5% of people will be diag-
nosed with lung cancer during their lifetime and approximately one-third of 
patients with NSCLC have a stage III presentation. Assuming this about 
1,550 patients in Austria (2014) had stage III NSCLC at the time of diagno-
sis. The average age at diagnosis is approximately 70 years [10].  
 
A0005: What are the symptoms and the burden of NSCLC? 
Many lung cancers are not symptomatic until they have spread. Symptoms 
of NSCLC include incessant cough, bloody sputum, chest pain, wheezing or 
hoarseness, weight loss or loss of appetite, shortness of breath, fatigue, and 
recurrent bronchitis or pneumonia. Lung cancer may metastasize to bone, 
brain, liver or lymph nodes causing pain, headaches, improper balance, sei-
zures, jaundice or lumps near the body’s surface [9]. 
 
A0003: What are the known risk factors for NSCLC? 
The risk of lung cancer increases with age, tobacco use, radiation exposure, 
air pollution, and occupational exposure to asbestos, arsenic, chromium be-
ryllium, nickel, second-hand smoking and other agents. The risk of develop-
ing lung cancer is tenfold higher in smokers compared to lifetime non-
smokers. Smoking cessation decreases precancerous lesions and reduces the 
risk of developing lung cancer [9].  
 
 
staged I–IV by 
invasiveness 
 
metastasize to bone, 
liver, brain, lymph nodes 
52–58% present with 
advanced cancer; 
relapse and metastasize 
early 
4,716 Austrians were 
diagnosed with NSCLC 
in 2014 
 
 
 
 
average age at diagnosis 
~70 years 
NSCLC symptoms: 
cough, chest pain, 
weight loss, shortness of 
breath 
main risk factor: 
smoking 
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A0024: How is NSCLC currently diagnosed according to published guide-
lines and in practice? 
While some lung cancers may be found through screening, most are identi-
fied when they become symptomatic. Following a clinical history and physi-
cal exam, a chest x-ray may be done to identify any abnormal areas in the 
lungs. A computed tomography (CT) scan may show the size, shape and lo-
cation of any lung tumours or enlarged lymph nodes, and guide a needle bi-
opsy if a suspected area is identified. Lung cancer is diagnosed by examin-
ing cells derived through biopsy or sputum sampling for the presence of 
cancer cells. Immunohistochemical (IHC), molecular tests, and liquid biop-
sy may be conducted to identify specific changes in the gene expression of 
cancer cells to target first-line treatment for NSCLC patients with genetic 
aberrations in EGFR, BRAF, ALK or ROS1 genes. In addition to tumour 
genotyping, all patients may be assessed for PD-L1 expression on tumour 
cells and tumour-infiltrating immune cells using the Ventana PD-L1 
(SP142) IHC assay [12] 
 
 
 
6 Current treatment 
A0025: How is NSCLC currently managed according to published guide-
lines and in practice? 
Depending on the tumour stage, histology, and the patient’s overall health, 
surgery, radiation therapy and/or platinum-based chemotherapy may be 
used alone or in combination to treat NSCLC. Treatment per NSCLC stages 
involves the following options [12]: 
 Stage I and II NSCLC patients typically undergo surgery to remove 
the cancer. Stage II patients may benefit from postoperative adjuvant 
chemotherapy.  
 Patients with stage I or II cancers that are not surgical candidates, 
due to co-morbidities or limited lung function, may undergo local ra-
diation therapy.  
 Stage III NSCLC patients are highly heterogeneous and may undergo 
a combination of treatments depending on the extent and localization 
of disease as well as prior treatments.  
 Patients with stage IV disease are treated with systemic therapy or a 
symptom-based palliative approach.  
 
 
 
 
 
 
 
diagnosis: x-ray, CT, and 
biopsy 
 
 
 
 
 
PD-L1 status: IHC assay 
treatment by stage: 
surgery, radiation 
therapy, chemotherapy 
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In appropriately selected patients, chemotherapy, molecularly targeted ther-
apy, and/or immunotherapy may extend survival in stage III NSCLC: 
 While the optimal chemotherapy regimen for use with concurrent ra-
diotherapy is not known, cisplatin plus etoposide, carboplatin, or vi-
norelbine and paclitaxel are commonly used. The combination of 
pemetrexed and cisplatin has also emerged as an option for stage III 
patients with non-squamous histology [12].  
 The standard dose fractionation regimen of radiotherapy with chemo-
therapy for stage III NSCLC is 60 Gy in 30 daily fractions. Intensity-
modulated radiation therapy is preferred over 3D radiotherapy due to 
the reduced risk for pneumonitis.  
 NSCLC patients with genetic alterations in EGFR may benefit from 
tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib, or 
osimertinib. Patients with ALK translocations may benefit from cri-
zotinib, ceritinib, alectinib, or brigatinib therapy. First-line therapy 
for ROS1-translocated NSCLC is crizotinib; carbozantinib may be ef-
fective for crizotinib-resistant cancers. First-line therapy for stage IV 
patients with BRAF V600E is combination dabrafenib plus tramet-
inib [12]. 
 Pembrolizumab, nivolumab, and atezolizumab block PD-L1 on T-
lymphocytes and are used as second-line therapies for advanced 
NSCLC [12] .  
 No targeted therapies or immunotherapies were available for stage III 
NSCLC patients until durvalumab was approved. 
 
 
 
7 Evidence 
A literature search was conducted on 19 October 2017 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “durvalumab”, “Imfinzi”, “NSCLC” and “non-small cell 
lung cancer”. The manufacturer was also contacted and submitted a refer-
ence and a supplemental appendix that had already been identified by sys-
tematic literature search. A manual search yielded three FDA approval doc-
uments [2, 5, 6], an EMA marketing authorization application notification 
[7], five clinical guidance documents [9, 11, 12, 14, 16], three mechanism of 
action articles [17-19], a phase II study report [20], a phase III protocol [21], 
a supplementary appendix [22], two statistical documents [10, 15] and two 
cost editorials [23, 24]. Ongoing trials information was found on 
www.clinicaltrials.gov. Overall, 131 references were identified.  
A phase III study, a phase I/II study, and a phase II study contributed to the 
evidence regarding efficacy and safety of durvalumab for patients with stage 
III NSCLC after prior chemoradiotherapy. Included in this report are:  
 PACIFIC, phase III [3, 22] 
 Study 1108, phase I/II [25, 26] 
 ATLANTIC, phase II [20, 27] 
optimal chemotherapy 
regimen for use with 
concurrent radiotherapy 
is not known 
 
 
 
 
 
 
targeted therapies 
 
 
 
 
 
immunotherapies 
systematic literature 
search in 5 databases:  
112 hits 
 
 
manual search: 19 
additional references 
overall: 131 references 
included: 3 studies 
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To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [28]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patient and treating physician, selective 
outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table 5 of the Appendix. 
To evaluate the magnitude of “clinically meaningful benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS v1.1) was used [29, 30]. Additionally, an adapted version (due to per-
ceived limitations) of the ESMO-MCBS was applied [31]. Details of the 
magnitude of the clinically meaningful benefit scale are reported in Table 3. 
 
 
7.1 Clinical efficacy and safety –  
phase III study 
PACIFIC (NCT02125461) is a multicentre, randomised, placebo-controlled, 
phase III study involving 713 patients with stage III, unresectable NSCLC 
without progression following concurrent platinum-based chemoradiothera-
py [3, 22]. Efficacy analyses were based on all randomly assigned patients 
comprising the intent-to-treat (ITT) population. Safety analyses involved 
709 patients who received at least one dose of study drug as consolidation 
therapy (as-treated population). While patients provided optional archived 
tumour-tissue samples for PD-L1 testing, enrolment was not restricted by 
level of PD-L1 expression.  
Study participants were adults (≥18 years) with histologically or cytological-
ly confirmed stage III, locally advanced, unresectable NSCLC; World 
Health Organization (WHO) performance status 0–1; who had received two 
or more cycles of platinum-based chemotherapy concurrent with radiother-
apy, with a life expectancy greater than 12 weeks. Patients were excluded if 
they were previously exposed to anti-PD-1 or PD-L1 antibodies; received 
immunotherapy or a study drug within four weeks of first dose; had active or 
prior autoimmune disease or immunodeficiency; uncontrolled concurrent 
illness or active infections; unresolved toxic effects or pneumonitis from pri-
or chemoradiotherapy (grade ≥2, Common Terminology Criteria for Ad-
verse Events [CTCAE]).  
Patients were randomized 2:1 to receive durvalumab (10 mg/kg IV) or 
matching placebo every 2 weeks for up to 12 months, disease progression or 
unacceptable toxicity. They were stratified according to age (<65 years ver-
sus ≥65 years), sex, and smoking history (current or former smoker versus 
never smoked). The study drug was administered within 42 days after receiv-
ing two or more cycles of platinum-based chemotherapy. Patients received 
chemotherapy containing etoposide, vinblastine, vinorelbine, pemetrexed, 
paclitaxel or docetaxel concurrently with definitive radiation therapy (54-66 
Gy), in which the mean dose to lung was <20 Gy, the volume of lung paren-
chyma that received >20 Gy was <35%, or both. At interim analysis Febru-
ary 13, 207 (median follow-up of 14.5 months), the median number of infu-
sions received was 20 (range, 1–27) for durvalumab and 14 (range, 1–26) for 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
PACIFIC: durvalumab 
versus placebo in 713 
unresected, stage III 
NSCLC patients 
following platinum-
based 
chemoradiotherapy 
ITT stratified by age, 
sex, and smoking history 
durvalumab 10 mg/kg IV 
versus placebo every 2 
weeks 
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placebo. The median relative dose intensity, defined as the ratio of delivered 
to planned, was 100% in each group (range, 29–100%) for duvalumab and 
for placebo (range, 50–100%).  
The co-primary endpoints were PFS according to the Response Evaluation 
Criteria in Solid Tumours (RECIST version 1.1) as assessed by blinded in-
dependent central review (BICR) and overall survival (OS). Secondary end-
points included the percentage of patients who were alive without disease 
progression at 12 and 18 months, the ORR, DOR, and the time to death or 
distant metastasis (TTDM), as assessed by BICR, OS at 24 months, and safe-
ty. Efficacy was assessed every 8 weeks for the first 12 months and every 12 
weeks thereafter.  
The ITT population (n = 713) had a median age of 64 years (range 23–90), 
70% were male, 69% were Caucasian, 53% were stage IIIA at entry, 54% had 
non-squamous histology, and 91% were current or former smokers. Approx-
imately 54% had prior cisplatin-based chemotherapy and 42% had prior 
carboplatin-based chemotherapy concurrently with radiation (54–66 Gy). 
EGFR mutations were observed in 6% of patients (6.1% durvalumab versus 
5.9% placebo). Approximately 22.3% of patients had PD-L1 expression of 
≥25% on tumour cells (24.2% durvalumab versus 18.6% placebo), 41.0% of 
patients had PD-L1 expression of <25% on tumour cells (39.3% durval-
umab versus 44.3% placebo), and PD-L1 status was unknown in 36.7% of 
patients. Detailed patient characteristics, including inclusion and exclusion 
criteria are reported in Table 4 and study quality is described in Table 5 of 
the appendix, respectively. Clinical efficacy data are presented in Table 1 
and AEs are listed in Table 2.  
 
7.1.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of durvalumab on mortality? 
Due to the low maturity of data, an analysis of OS was not planned at the 
time of the interim analysis for PFS. The first OS interim analysis will be at 
the time of final analysis for PFS.  
 
D0006: How does durvalumab affect progression (or recurrence) of NSCLC? 
At interim analysis, February 13, 2017, 371 patients had disease progression 
(214/476 durvalumab versus 157/237 placebo). At a median follow-up of 14.5 
months (range 0.2–29.9), durvalumab patients had a BICR-assessed median 
PFS of 16.8 months (95% CI 13.0–18.1) compared to 5.6 months (95% CI 
4.6–7.8) for stage III NSCLC patients treated with placebo. Compared with 
placebo, durvalumab improved BICR-assessed PFS (stratified hazard ratio 
[HR] for disease progression or death 0.52 [95% CI 0.42–0.65]; two-sided 
p<0.001).  
The proportion alive and progression-free rate at 12 months (APF12), as as-
sessed by BICR, was 55.9% (95% CI 51.0–60.4) with durvalumab versus 
35.3% (95% CI 29.0–41.7) with placebo. At 18 months, the proportion alive 
and progression-free (APF18) was 44.2% (95% CI 37.7–50.5) with durval-
umab versus 27.0% (95% CI 19.9–34.5) with placebo.  
co-primary endpoints: 
PFS and OS 
secondary endpoints: 12 
and 18-month PFS rates, 
ORR, DOR, TTDM and 
safety 
ITT: median age 64 
years, 53% stage IIIA, 
91% smokers, 41% PD-
L1 expression <25% on 
tumour cells 
OS: not planned for 
interim analysis  
median PFS in ITT: 16.8 
months for durvalumab 
vs 5.6 months for 
placebo 
APF12:  
durvalumab: 56% 
placebo: 35% 
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Patients receiving durvalumab demonstrated greater PFS than placebo re-
cipients regardless of their PD-L1 expression prior to chemoradiotherapy 
(HR 0.59 [95% CI 0.43–0.82] for PD-L1 expression <25% and 0.41 [95% CI 
0.26-0.65] for PD-L1 expression ≥25%). While the majority of patients were 
smokers, durvalumab recipients who were non-smokers exhibited greater 
PFS over placebo recipients who were smokers.  
 
D0005: How does durvalumab affect symptoms and findings (severity, fre-
quency) of NSCLC? 
The ORR, as assessed by BICR, was 28.4% (126/443) for durvalumab versus 
16.0% (34/213) for placebo (p<0.001) (treatment effect [TE] 1.78 [95% CI 
1.27–2.51]; p<0.001). The median DOR was not reached (NR) in the dur-
valumab group and 13.8 months (95% CI 6.0–NR) in the placebo group (TE 
0.43 [95% CI 0.22–0.84]). Of the patients that responded to durvalumab, 
72.8% had an ongoing response at 12 and 18 months compared with 56.1% 
and 46.8%, respectively, of placebo recipients. 
The TTDM was 23.2 months (95% CI 23.2–NR) with durvalumab versus 
14.6 months (95% CI 10.6–18.6) with placebo (HR 0.52 [95% CI 0.39–0.69]; 
two-sided p<0.001). The frequency of BICR-assessed new lesions was 20.4% 
with durvalumab and 32.1% with placebo. The incidence of new brain me-
tastases was 5.5% in durvalumab recipients and 11.0% in placebo recipients.  
 
D0011: What is the effect of durvalumab on patients̕  body functions? 
Durvalumab may cause immune-mediated AEs including pneumonitis, 
hepatitis, colitis, nephritis, endocrinopathies, immunogenicity and infection 
[2]. Immune-mediated AEs, of any cause and grade, were observed in 
115/475 (24.2% of) patients in the durvalumab group and 19/234 (8.1% of) 
patients in the placebo group. Grade 5 immune-mediated AEs were reported 
in 4 (0.8% of) durvalumab recipients and 3 (1.3% of) placebo recipients. 
Grade 3 or 4 AEs occurred in 3.4% of durvalumab-treated patients and 2.6% 
of placebo-treated patients. Treatments for immune-mediated AEs were is-
sued to 14.3% and 5.6% of patients receiving durvalumab and placebo, re-
spectively; including high-dose glucocorticoids (8.2% and 4.3%), endocrine 
therapy (10.7% and 1.3%), and other immunosuppressive agents (0.4% both 
groups) [3].  
 
D0012: What is the effect of durvalumab on generic health-related quality of 
life? 
No evidence was reported regarding the effect of durvalumab on generic 
health-related quality of life (QoL).  
 
D0013: What is the effect of durvalumab on disease-specific quality of life? 
No evidence was reported regarding the effect of durvalumab on disease-
specific QoL.  
 
 
PFS benefit irrespective 
of PD-L1 expression 
level 
ORR:  
durvalumab: 28.4% 
placebo: 16.0% 
DOR: 
durvalumab: NR 
placebo: 13.8 months 
TTDM: 
durvalumab: 23.2 
months 
placebo: 14.6 months 
treatment for immune-
mediated AEs: 
durvalumab: 14.3% 
placebo: 5.6% 
generic health-related 
QoL: no evidence 
disease-specific QoL: 
no evidence 
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Table 1: Efficacy results of PACIFIC [3] 
Descriptive statistics and 
estimate variability 
Treatment group Durvalumab Placebo 
Number of subjects 476 237 
OS, n (%) NA NA 
Median PFS, months 
 
16.8 
(95% CI 13.0–18.1) 
5.6 
(95% CI 4.6–7.8) 
PFS, n (%) (follow-up: 14.5 
months) 214/476 (45) 157/237 (66) 
APF12, % 55.9 
(95% CI 51.0–60.4) 
35.3 
(95% CI 29.0–41.7) 
APF18, % 44.2 
(95% CI 37.7–50.5) 
27.0 
(95% CI 19.9–34.5) 
ORR, n (%) 
 
12-month response, n (%) 
18-month response, n (%) 
126 (28.4) 
(95% CI 24.3–32.9) 
347 (72.8) 
347 (72.8) 
34 (16.0)  
(95% CI 11.3–21.6) 
133.2 (56.1) 
110 (46.8) 
Best overall response, n (%) 
CR 
PR 
SD 
PD 
UE 
 
6 (1.4) 
120 (27.1) 
233 (52.6) 
73 (16.5) 
10 (2.3) 
 
1 (0.5) 
33 (15.5) 
119 (55.9) 
59 (27.7) 
1 (0.5) 
Median DOR, months NR 13.8 
6.0–NR 
Median TTDM 23.2 
(95% CI 23.2–NR) 
14.6 
(95% CI 10.6–18.6) 
Frequency of new lesions, n (%) 
New brain metastases, n (%) 
97 (20.4) 
26 (5.5) 
76 (32.1) 
26 (11.0) 
Effect estimate per com-
parison 
 
Comparison groups Durvalumab versus placebo 
OS 
Co-primary endpoint 
NA NA 
BICR-assessed PFS  
Co-primary endpoint 
Stratified HR 0.52 
95% CI 0.42–0.65 
Two-sided p value <0.001 
Investigator-assessed PFS  Stratified HR 0.61 
95% CI 0.50–0.76 
Two-sided p value P<0.001 
PFS PD-L1 <25% HR 0.59 
95% CI 0.43–0.82 
p value NA 
PFS PD-L1 ≥25% HR 0.41 
95% CI 0.26–0.65 
p value NA 
ORR 
Secondary endpoint 
TE 1.78 
95% CI 1.27–2.51 
p value <0.001 
DOR TE 0.43 
95% CI 0.22–0.84 
p value NA 
TTDM HR 0.52 
95% CI 0.39–0.69 
Two-sided p value <0.001 
Abbreviations: BICR = blinded independent review committee; CI = confidence interval; CR = complete response; DOR = duration of 
response; HR = hazard ratio; NA = not analysed; NR = not reached; OS = overall survival; PD = progressive disease; PR = partial 
response; SD = stable disease; TE = treatment effect; TTDM = time to death or distant metastasis; UE = unable to evaluate 
 
Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung 
cancer after prior chemoradiotherapy 
LBI-HTA | 2017 17 
7.1.2 Safety 
 
C0008: How safe is durvalumab in relation to the comparator(s)? 
Treatment-related AEs were reported in 322/475 (67.8% of) patients in the 
durvalumab group and 125/234 (53.4% of) patients in the placebo group. 
Serious AEs occurred in 136/475 (28.6% of) durvalumab recipients and 
53/234 (22.6% of) placebo recipients. Death due to AEs occurred in 4.4% 
and 5.6% of durvalumab and placebo patients, respectively. Grade 5 treat-
ment-related AEs occurred in seven (1.5% of) durvalumab recipients (n = 4 
[0.8%] with pneumonitis, n = 2 [0.4%] with cardiac arrest, and n = 1 
[0.2%]) each with cardiomyopathy, right ventricular failure, respiratory dis-
tress, respiratory failure, increased brain natriuretic peptide, and radiation 
pneumonitis right ventricular failure, increased level of brain natriuretic 
peptide, and unknown cause) and three (1.3% of) placebo recipients (n = 2 
[0.9%] with pneumonitis and 1 [0.4%] cause unknown]. Grade 3 or 4 AEs of 
any cause were reported in 29.9% of durvalumab recipients and 26.1% of 
placebo recipients. Pneumonia and anaemia, the most common grade 3 or 4 
AE, were observed in 4.4% and 2.9% of patients receiving durvalumab, and 
3.8% and 3.4% of patients receiving placebo, respectively. The most com-
mon AEs of any cause and grade in the durvalumab group were cough 
(35.4%), pneumonitis (33.9%), fatigue (23.8%), dyspnoea (22.3%), diarrhoea 
(18.3%), and pyrexia (14.7%).  
AEs of special interest, regardless of cause, were reported in 66.1% of pa-
tients receiving durvalumab and 48.7% of patients receiving placebo; most 
frequently diarrhoea (18.3% and 18.8%), pneumonitis (12.6% and 7.7%), 
rash (12.2% and 7.3%), and pruritus (12.2% and 4.7%). Concomitant treat-
ments for AEs of special interest were issued to 42.1% of durvalumab recipi-
ents and 17.1% of placebo recipients, including glucocorticoids (15.2% and 
6.8%), high-dose glucocorticoids (8.8% and 5.1%), endocrine therapy (11.6% 
and 1.3%, respectively) and other immunosuppressive agents (0.4% both 
groups). 
 
C0002: Are the harms related to dosage or frequency of applying 
durvalumab? 
Severe infusion-related reactions have been reported in patients receiving 
durvalumab. It is necessary to interrupt or infuse slowly in patients with 
mild or moderate infusion reactions and discontinue use in patients with 
grade 3 or 4 reactions [2]. By interim analysis, the number of infusions re-
ceived by study participants was 20 (range 1–27) in the durvalumab group 
and 14 (range 1–26) in the placebo group; 6.3% and 5.1% of patients were 
still receiving durvalumab at the time of data cut-off, respectively. The me-
dian relative dose intensity was 100% in each group (range 29–100% for 
durvalumab, 50–100% for placebo) with an overall median follow-up of 14.5 
months [3]. 
Durvalumab may be withheld and corticosteroids administered to manage 
moderate pneumonitis, hepatitis, colitis, diarrhoea, nephritis, or dermatitis. 
Moderate hypothyroidism, adrenal insufficiency, hypophysitis, type 1 diabe-
tes mellitus, or infections may require withholding of durvalumab and ad-
ministration of hormone replacement therapies, insulin or anti-infective 
agents. Treatment may be resumed when AEs return to grade 1 severity and 
treatment-related AEs: 
durvalumab: 68% 
placebo: 53% 
 
AE-related deaths:  
durvalumab: 4.4% 
placebo: 5.6% 
 
most common AEs: 
cough, pneumonitis, 
fatigue, dyspnoea, 
diarrhoea and pyrexia 
AEs of special interest: 
diarrhoea, pneumonitis, 
rash and pruritus  
infusion reactions: 
interrupt, infuse slowly, 
or discontinue 
moderate AEs: 
discontinue, administer 
corticosteroids 
severe AE: discontinue 
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the corticosterioid dose has been reduced to <10 mg/day of prednisone or 
equivalent. Durvalumab may be discontinued to manage grade 3 or 4 AEs 
based on the severity of the adverse reaction [2].  
Approximately 73/476 (15.4% of) durvalumab patients and 23/237 (9.8% of) 
placebo patients discontinued treatment due to AEs. Pneumonitis and 
pneumonia, the most frequent AEs leading to discontinuation of 
durvalumab and placebo, were reported in 6.3% and 1.1% of patients 
receiving durvalumab, and 4.3% and 1.3% of patients receiving placebo, 
respectively. Grade 3 or 4 pneumonitis and pneumonia occurred in 3.4% 
and 4.4% of durvalumab recipients and 2.6% and 3.8% of placebo recipients, 
respectively [3].  
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of durvalumab? 
Study participants had a median age of 64 years (range, 23–90 years) and 
good performance status (WHO 0–1). Patients with a history of autoimmune 
disease, immunodeficiency, active infections or uncontrolled illnesses were 
excluded from study. While PFS benefit was observed across age subgroups 
(<65 years versus ≥65 years) [3], clinical specificity of elderly patients with 
comorbidities, co-medications, reduced functional reserve, and immunose-
nescence may affect the efficacy and or toxicity of immune-checkpoint in-
hibitors [32, 33]. The safety and efficacy of durvalumab has not been estab-
lished in pediatric patients and the pharmacokinetics are unknown in pa-
tients with severe renal impairment (CLcr 15–29 ml/min), moderate (biliru-
bin >1.5–3.0 times ULN and any AST) or severe hepatic impairment (bili-
rubin >3.0 times ULN and any AST) [2]. 
Based on its mechanism of action durvalumab may cause foetal harm and 
adverse reactions in breastfed infants, females are advised to use effective 
contraception and not to breast feed for at least three months following the 
last dose of durvalumab [2].  
 
leading causes of 
discontinuation: 
pneumonitis and 
pneumonia 
susceptibles: elderly, 
immune compromised, 
comorbid, reduced 
functional status 
durvalumab may cause 
foetal harm 
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Table 2: Most frequent adverse events of any cause of PACIFIC [3] 
 
Adverse Event (according  
to CTCAE version 4.03) 
 
Durvalumab 
(n = 475) 
Placebo 
(n = 234) 
 Any Grade 
n (%) 
Grade 3 or 4 
n (%) 
Any Grade 
n (%) 
Grade 3 or 4 
n (%) 
Any event 460 (96.8) 142 (29.9) 222 (94.9) 61 (26.1) 
Cough 168 (35.4) 2 (0.4) 59 (25.2) 1 (0.4) 
Pneumonitis or radiation 
pneumonitis 
161 (33.9) 16 (3.4) 58 (24.8) 6 (2.6) 
Fatigue 113 (23.8) 1 (0.2) 48 (20.5) 3 (1.3) 
Dyspnoea 106 (22.3) 7 (1.5) 56 (23.9) 6 (2.6) 
Diarrhoea 87 (18.3) 3 (0.6) 44 (18.8) 3 (1.3) 
Pyrexia 70 (14.7) 1 (0.2) 21 (9.0) 0 (0) 
Decreased appetite  68 (14.3) 1 (0.2) 30 (12.8) 2 (0.9) 
Nausea 66 (13.9) 0 (0) 31 (13.2) 0 (0) 
Pneumonia 62 (13.1) 21 (4.4) 18 (7.7) 9 (3.8) 
Arthralgia 59 (12.4) 0 (0) 26 (11.1) 0 (0) 
Pruritus 58 (12.2) 0 (0) 11 (4.7) 0 (0) 
Rash 58 (12.2) 1 (0.2) 17 (7.3) 0 (0) 
Upper respiratory tract 
infection 
58 (12.2) 1 (0.2) 23 (9.8) 0 (0) 
Constipation 56 (11.8) 1 (0.2) 20 (8.5) 0 (0) 
Hypothyroidism 55 (11.6) 1 (0.2) 4 (1.7) 0 (0) 
Headache 52 (10.9) 1 (0.2) 21 (9.0) 2 (0.9) 
Asthenia 51 (10.7) 3 (0.6) 31 (13.2) 1 (0.4) 
Back pain 50 (10.5) 1 (0.2) 27 (11.5) 1 (0.4) 
Musculoskeletal pain 39 (8.2) 3 (0.6) 24 (10.3) 1 (0.4) 
Anaemia 36 (7.6) 14 (2.9) 25 (10.7) 8 (3.4) 
Abbreviations: CTCAE = common terminology for cancer adverse events 
 
 
7.2 Clinical effectiveness and safety –  
further studies 
Study 1108 (NCT01693562) is an ongoing, multicentre, open-label, phase 
I/II study to evaluate the safety and clinical activity of durvalumab mono-
therapy in subjects with multiple advanced solid tumours, including 
NSCLC [25]. Patients received 10 mg/kg of durvalumab intravenously every 
2 weeks until disease progression or unacceptable toxicity, for up to 12 
months. Clinical response is based on investigator-assessment (RECIST 
v1.1) at 6, 12, and 16 weeks, then every 8 weeks. Retreatment was permitted 
only upon progression after 12 months of therapy in patients with disease 
control. Safety was evaluated prior to each dose (CTCAE v4.03) through 90 
days after the last dose. Tumour PD-L1 expression was assessed using the 
Ventana PD-L1 (SP263) assay.  
Study 1108: 304 NSCLC 
patients given 
durvalumab 10 mg/kg IV 
every 2 weeks, median 6 
doses 
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As of April 2016, 304 NSCLC patients received durvalumab, 144 (45%) had 
non-squamous and 160 (53%) had squamous histology, median age was 65 
years (range, 26–87), ECOG performance status was 0 in 24% and 1 in 76%, 
and 85% were smokers. Durvalumab monotherapy was associated with im-
proved ORR and OS in PD-L1-positive treatment naïve NSCLC of squa-
mous or non-squamous histology [25, 26]. At a median of 6 doses (range 1-
27), the ORR was 25% for PD-L1-positive patients versus 6% for PD-L1-
negative patients. The ORR was 29%, 26%, and 22% as first-, second-, and 
third-line therapy, respectively, for the PD-L1-positive subgroup, and 11%, 
4%, and 6% for the PD-L1-negative subgroup. The median OS in PD-L1-
positive and PD-L1-negative subgroups was 17.8 months and 8.2 months as 
second-line; and 13.0 months and 7.1 months as ≥ third-line, respectively. 
The 12-month OS rate in PD-L1-positive and PD-L1-negative subgroups 
was 55.8% and 38.8% as second-line; and 51.1% and 36.8% as ≥ third-line, 
respectively. Durvalumab-related AEs, of any grade, were reported in 57% of 
patients, most commonly fatigue (17%), decreased appetite (9%), and diar-
rhoea (9%). Grade ≥3 drug-related AEs were reported in 10% of patients; 
most frequently fatigue, hyponatremia, and colitis (1% each). Pneumonitis 
and colitis, the most frequent AEs leading to discontinuation of durvalumab 
in 5% of patients, occurred in 6 (3%) and 5 (2%) of patients, respectively 
[25].  
ATLANTIC (NCT02087423) is an ongoing, multicentre, single-arm, open-
label, phase II study assessing the efficacy and safety of durvalumab (10 
mg/kg IV every 2 weeks) as third-line treatment for patients with locally ad-
vanced or metastatic NSCLC with known PD-L1 status, who progress fol-
lowing two or more previous therapies, including platinum-based chemo-
therapy [34]. While the study contains three cohorts, final results were re-
ported for cohort 2 and 3 that had EGFR/ALK wild-type or unknown status. 
Patients in cohort 3 expressed PD-L1 on at least 90% or more tumour cells, 
as assessed by Roche Ventana SP263 assay; while 61% of patients in cohort 2 
expressed PD-L1 on at least 25% or more tumour cells and 39% had less 
than 25% PD-L1 expression.  
Overall, 265 patients with a median age of 62 years were included in cohort 
2, and 68 patients with a median age of 61 years in cohort 3 [34]. The ORR 
was 7.5%, 16.4%, and 30.9% in patients with tumour PD-L1 expression of 
<25%, ≥25%, and ≥90%, respectively. In cohort 2, the median PFS was 3.3 
months and 1.9 months in patients with high and low/negative PD-L1 ex-
pression, respectively. In cohort 3, the median PFS was 2.4 months. In co-
hort 2, the 12-month OS rate was 47.7% and 34.5% for patients with high 
and low/negative PD-L1 expression, respectively. In cohort 3, the 12-month 
OS rate was 50.8%. Overall, 10.2% of patients had grade ≥3 treatment-
related AEs, and 2.7% of treatment-related AEs lead to drug discontinua-
tion.  
 
 
 
 
ORR:  
PD-L1-positive: 25% 
PD-L1-negative: 6% 
 
 
 
 
 
 
 
 
 
12-month OS rate: 
PD-L1-positive: 55.8% 
PD-L1-negative: 38.8% 
 
 
5% discontinue due to 
pneumonitis and colitis 
ATLANTIC: durvalumab 
10 mg/kg IV every 2 
weeks as 3rd line for 
NSCLC who progress on 
≥2 therapies 
ORR:  
PD-L1<25%: 7.5% 
PD-l1≥25%: 16.4% 
PD-L1≥90%: 30.9% 
 
PFS:  
PD-L1<25%: 1.9 months 
PD-l1≥25%: 3.3 months 
PD-L1≥90%: 2.4 months 
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8 Estimated costs 
A0021: What is the reimbursement status of durvalumab? 
Currently, there are no price estimates for Europe. Durvalumab costs ap-
proximately US $15,000 per month [24], or US $180,000 per year [23].  
 
 
 
9 Ongoing research 
Several studies are ongoing to investigate durvalumab as monotherapy or in 
combination with immune checkpoint inhibitors, tyrosine kinase inhibitors, 
or other anti-cancer agents to treat advanced NSCLC. In November 2017, 
searches of www.clinicaltrials.gov and http://www.clinicaltrialsregister.eu 
using the search terms “durvalumab” and “NSCLC” yielded 40 registered 
studies (eight phase III, 18 phase II, eight phase I/II, and six phase I). Most 
studies were industry-sponsored or conducted in collaboration with indus-
try.  
Selected ongoing phase III studies evaluating durvalumab as monotherapy 
(MYSTIC, PEARL, ARCTIC, PACIFIC), in combination with 
tremelimumab (MYSTIC, NEPTUNE, ARCTIC) in first-line (PEARL, 
MYSTIC, NEPTUNE), second-line (PACIFIC), third-line (ARCTIC) set-
tings for NSCLC, or the addition of durvalumab plus tremelimumab to 
standard care (POSEIDON) for metastatic NSCLC: 
 NCT03003962: PEARL is a randomised, open-label, multicentre 
study to determine the efficacy and safety of durvalumab versus 
platinum-based chemotherapy in the first-line treatment of ad-
vanced NSCLC in patients with wild-type EGFR and ALK and 
high expression of PD-L1. Estimated primary completion date is 
October 2018.  
 NCT02453282: MYSTIC is a randomised, open-label, multicentre 
study to evaluate the efficacy and safety of durvalumab plus 
tremelimumab combination therapy and durvalumab monotherapy 
versus platinum-based chemotherapy in the first-line treatment of 
patients with EGFR and ALK wild-type locally advanced or meta-
static NSCLC. Estimated primary completion date is June 2018. 
 NCT02542293: NEPTUNE is a randomised, open-label, multicen-
tre study to assess the efficacy of durvalumab plus tremelimumab 
versus platinum-based chemotherapy in the first-line treatment of 
patients with EGFR and ALK wild-type advanced or metastatic 
NSCLC. Estimated primary completion date is October 2018.  
 NCT02352948: ARCTIC is a randomised, open-label, multicentre 
study to evaluate the safety and efficacy of durvalumab monothera-
py or in combination with tremelimumab determined by PD-L1 
expression versus standard care in patients with locally advanced or 
estimate: US 
$15,000/month 
Austria: no price 
estimate available 
40 registered studies 
 
8 industry sponsored 
ongoing phase III 
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metastatic NSCLC. Estimated primary completion date is Novem-
ber 2017.  
 NCT03164616: POSEIDON is a randomised, open-label, multicen-
tre study to determine the efficacy of durvalumab or durvalumab 
plus tremelimumab in combination with platinum-based chemo-
therapy for first-line treatment of patients with metastatic NSCLC. 
Estimated primary completion date is July 2019.  
 NCT02273375: ADJUVANT is a randomised, double-blind, placebo 
controlled study to find out whether it is better to receive durval-
umab or to receive no further treatment following surgery and pos-
sibly chemotherapy for NSCLC that is PD-L1 positive. Estimated 
primary completion date is January 2025.  
 NCT02454933: CAURAL is a randomised, open-label, multicentre 
study to assess the safety and efficacy of osimertinib in combination 
with durvalumab versus osimertinib monotherapy in patients with 
locally advanced or metastatic EGFR T790 mutation-positive 
NSCLC who have received prior EGFR tyrosine kinase inhibitor 
therapy. Estimated primary completion date is August 2017.  
 
 
 
10 Discussion 
In May 2017, the FDA approved durvalumab, and a complementary diag-
nostic assay for PD-L1 expression (VENTANA PD-L1 (SP263) Assay), for 
treating locally advanced or MUC with disease progression following plati-
num-based chemotherapy. In July 2017, durvalumab was granted FDA-
breakthrough therapy designation as consolidation therapy within 42 days 
after chemoradiotherapy for patients with stage III NSCLC whose disease 
had not progressed following platinum-based chemoradiotherapy [5]. In Oc-
tober 2017, durvalumab was granted priority review for a supplemental bio-
logics license application based on PFS results from the phase III PACIFIC 
study [6]. Durvalumab does not currently have market authorisation in Eu-
rope for any indication. However, in October 2017, an MAA for durvalumab 
was submitted to the EMA for the treatment of patients with stage III, unre-
sectable NSCLC whose disease had not progressed following platinum-based 
chemoradiotherapy [7, 8].  
FDA: licensed for MUC; 
granted priority review 
for NSCLC  
EMA: MAA submitted 
for stage III NSCLC in 
October 2017 
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PACIFIC, a randomised, placebo-controlled phase III study compared the 
safety and efficacy of durvalumab (10 mg/kg IV every 2 weeks) versus 
matching placebo in 713 patients with stage III, unresectable NSCLC with-
out progression following platinum-based chemoradiotherapy [3]. OS data 
were not mature at the time of interim analysis for PFS. Compared with pla-
cebo, durvalumab increased BICR-assessed median PFS by 11.2 months at a 
median follow-up of 14.5 months. The PFS benefit of durvalumab over pla-
cebo was observed irrespective of PD-L1 expression level prior to chemora-
diotherapy or smoking status. BICR-assessed ORR was 28.4% for durval-
umab versus 16.0% for placebo; while the median DOR was 13.8 months for 
placebo, it was not reached in the durvalumab group. Of those who respond-
ed to durvalumab, 72% had an ongoing response at 18-months, compared 
with 46.8% of placebo recipients, respectively. Durvalumab increased the 
TTDM by 9 months compared to placebo and lowered the incidence of new 
brain metastases by 5.5%.  
Treatment-related AEs occurred in 68% of durvalumab recipients and 
53.4% of placebo recipients. Durvalumab patients reported more immune-
mediated AEs than placebo recipients (24% versus 8%), and required more 
high-dose glucocorticoids (8.2% versus 4.3%) and endocrine therapies 
(10.7% versus 1.3%) as treatment. Pneumonitis and pneumonia, the leading 
causes of discontinuation, were reported in 6.3% and 1.1% of durvalumab 
patients and 4.3% and 1.3% of placebo patients.  
Results of the PACIFIC study hold some limitations. The first interim anal-
ysis for the co-primary endpoint of OS will be conducted at the time of final 
analysis for PFS. Evaluating PFS, ORR, TTDM, and discontinuation data 
are useful outcomes in clinical trials; however, follow-up is insufficient to 
evaluate OS and potential antibody formation, and 14.3% of durvalumab pa-
tients required treatment for immune-mediated AEs. No evidence was re-
ported regarding the effect of durvalumab on generic or disease-specific 
QoL. Generalizability of the results may be limited in that while the PACIF-
IC study participants were a median age of 64 years and had good perfor-
mance status, the average age at diagnosis is 70 years, the clinical specificity 
in elderly patients with comorbidities, reduced functional reserve and im-
munosenescence may affect the efficacy and or toxicity of durvalumab. 
While study participants received durvalumab after concurrent chemoradio-
therapy, it is not clear whether the same outcomes could be derived follow-
ing sequential chemoradiotherapy. 
The clinical efficacy results of PACIFIC are consistent with phase I/II data 
from Study 1108 and ATLANTIC in that durvalumab monotherapy im-
proves ORR and PFS in patients with squamous or non-squamous histology. 
However, in contrast to Study 1108 and ATLANTIC where higher PD-L1 
expression conferred increased OS, PFS and ORR, the PFS and ORR bene-
fits of durvalumab observed in PACIFIC occurred irrespective of baseline 
PD-L1 expression on tumour cells. While durvalumab may be an effective 
adjuvant therapy in stage III patients following chemoradiotherapy, further 
evaluation is needed regarding the relation between PD-L1 expression and 
response, and the mechanism of action between immunotherapy and chemo-
radiotherapy.  
PACIFIC: durvalumab 
increased PFS, ORR, 
TTDM compared to 
placebo 
 
durvalumab increased 
median PFS +11.2 month 
irrespective of prior PD-
L1 expression or 
smoking status 
 
durvalumab response 
was durable at 12- and 
18-months 
durvalumab resulted in 
immune-mediated AEs  
PACIFIC: first phase III 
demonstrating benefit 
in PFS, ORR, TTDM; lack 
OS and QOL data, 
susceptibles 
PACIFIC results contrast 
phase II data as PFS and 
ORR benefits of 
durvalumab occur 
irrespective of baseline 
PD-L1 expression 
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The PACIFIC is a randomised, double-blind, placebo-controlled, trial with 
few methodological limitations. There is no risk of bias in the generation of 
randomisation sequence or allocation concealment. Patients were stratified 
by age, sex and smoking status, and block-randomised 2:1 to durvalumab 
versus placebo via a centralised interactive web-based/voice-based randomi-
sation system. Efforts were made to minimise the time between randomisa-
tion and starting the drug. Patients, physicians and outcome assessors were 
blinded as the placebo was identical in appearance, study centre staff were 
blinded to allocation and only the dispensing pharmacist and the independ-
ent data monitoring committee were aware of unblinded data. Selective out-
come reporting is unlikely as all outcomes were reported as specified in the 
protocol with the exception of QoL and immunogenicity. The risk of bias 
may be increased by industry involvement in the study design, data analysis 
and reporting, however, the overall risk of bias at the study level is low.  
Given the non-curative setting of durvalumab and the statistically signifi-
cant primary endpoint PFS we applied form 2b of the ESMO-MCBS v1.1 in 
order to assess whether durvalumab satisfies the criteria for a “meaningful 
clinical benefit” (score 4 or 5). Both the original as well as the adapted ver-
sion of the MCBS were applied [29-31]. The application of the ESMO-
MCBS to the PACIFIC study resulted in a grade 4 and 3 in the original and 
the adapted version of the ESMO-MCBS, respectively (Table 3). Therefore, 
durvalumab only leads to a meaningful clinical benefit in the original scale, 
but not in the adapted framework. Differences in scores occur due to the 
higher implication of a plateau in the PFS curve and an improvement in the 
one year PFS in the original ESMO-MCBS. However, it needs to be taken 
into account that the calculation of the scores is only based on the analysis of 
the PACIFIC trial. 
While several studies are ongoing, trials are needed that directly compare 
the safety and efficacy of durvalumab with other immunotherapies such as 
nivolumab, pembrolizumab or atezolizumab, a PD-L1 antibody recently ap-
proved for pre-treated NSCLC irrespective of PD-L1 assessment. While 
comparison studies are lacking, cross-trial comparisons are cautioned due to 
differences in patient selection based on the different PD-L1 assays used 
across trials. The results of durvalumab alone or combined with 
tremelimumab, in first-line settings (NEPTUNE and MYSTIC) will define 
how durvalumab compares with pembrolizumab and nivolumab studies re-
garding first-line immunotherapy for advanced NSCLC.  
The cost of durvalumab is approximately US$ 15,000 per month, or US 
$180,000 per year. Currently, there are no cost estimates for Europe. There 
are approximately 4,716 new cases of lung cancer being diagnosed each year 
in Austria, and at least one third have stage III, locally advanced disease at 
diagnosis. 
low risk of bias: 
randomised, double-
blind, placebo-
controlled, industry 
funded 
ESMO-MCBS 
original: 4 
adapted: 3 
lack of comparative 
trials; results of 
durvalumab alone or 
combined with 
tremelimumab in first 
line will define use 
estimate: US 
$15,000/month 
Austria: no price 
estimate available 
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Overall, PACIFIC is the first fully published phase III randomised, placebo-
controlled trial to report that durvalumab increases PFS, ORR, DOR, and 
TTDM in patients with stage III NSCLC regardless of PD-L1 expression 
and histology, compared to placebo (at the time of interim analysis). While 
durvalumab provided durable PFS and ORR, OS and QoL data are awaited. 
Results from PACIFIC may hold limited external validity as participants 
are not entirely generalizable to clinical practice. Ongoing trials investigat-
ing durvalumab alone or in combination with tremelimumab are likely to 
inform how durvalumab compares with pembrolizumab and nivolumab as 
first-line immunotherapy for NSCLC. Further research is needed regarding 
the duration and timing of immunotherapy, the best regimen of chemoradi-
ation for combination and patient selection for greatest benefit based on 
predictive markers of efficacy and resistance [35].  
 
 
 
PACIFIC: first phase III 
RCT reporting benefit in 
PFS, ORR, DOR and 
TTDM in stage III NSCLC 
(interim analysis) 
 
OS and QoL data is 
missing 
 
further research is 
needed: e.g. duration 
and timing of 
immunotherapy 
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Table 3: Benefit assessment based on the original ESMO-MCBS v1.1 and the adapted ESMO-MCBS [29-31] 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form MG-ST 
Efficacy Safety 
AJ FM MG 
months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
durvalumab NSCLC NC 
OS & 
PFSA 2b ≤6 m 
OS: NA 
PFS: 11.21 
OS: NA 
PFS: 0.52 (0.42–0.65) HR ≤0.65 AND Gain ≥1.5 m 3 
+3.8% grade 
3–4 AEs, +5.6%  
discontinuation rate 
NA x 3 
Original 
ESMO-
MCBS 
durvalumab NSCLC NC OS & 
PFSA 
2b ≤6 m 
OS: NA 
PFS: 11.21 
OS: NA 
PFS: 0.52 (0.42–0.65) HR ≤0.65 AND Gain ≥1.5 m 
3 x NA +12 4 
Abbreviations: 
A
 = co-primary endpoints; AE = adverse event; AJ = Adjustments; CI = confidence interval; FM = final adjusted magnitude of clinical benefit grade; HR = hazard ratio; m = months; MG = median gain; NA 
= not available; NSCLC = non-small cell lung cancer; OS = overall survival; PE = primary endpoint; PFS = progression-free survival; PM = preliminary magnitude of clinical benefit grade; QoL = quality of life; ST = 
standard treatment 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjust-
ments separately. 
                                                             
1
 results are based on interim analysis 
2
 1 level upgrade due to a long term plateau in the PFS curve and a ≥10% improvement in PFS at 1 year (+20.6%) 
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12 Appendix  
Table 4: Characteristics of the PACIFIC trial 
Title: Durvalumab after chemoradiotherapy in stage III NSCLC [3, 22] 
Study identifier NCT02125461, D4191C00001, EudraCT 2014-000336-42, PACIFIC 
Design International (26 countries), multicentre (235 centres), randomized, double-blind, placebo-
controlled, phase III  
Duration of main phase: May 2014-April 2016: 709 of 713 patients randomized re-
ceived at least one dose of study drug (n=473 durvalumab, 
n=236 placebo) 
Interim analysis data cut-off: February 13, 2017 when 371 
patients had disease progression (n=214 durvalumab, 
n=157 placebo) 
Overall median follow-up: 14.5 months (range 0.2–29.9) 
Duration of Run-in phase: Not applicable, patients randomly assigned within 1–42 
days after chemoradiotherapy 
Duration of Extension phase: Not applicable 
Hypothesis 
Interventional 
The study was designed to evaluate the efficacy and safety of durvalumab compared with placebo 
as consolidation therapy following concurrent chemoradiation in patients with stage III unresec-
table NSCLC 
Funding AstraZeneca 
Treatments groups 
Durvalumab  
(n=476 ITT,  n=475 safety popula-
tion) 
10 mg/kg IV, infused over 60 minutes, every 2 weeks as 
consolidation therapy for up to 12 months 
Placebo 
(n=237, n=234 safety population) 
10 mg/kg IV, infused over 60 minutes, every 2 weeks as 
consolidation therapy for up to 12 months 
 Overall survival 
(co-primary endpoint) 
OS Time from date of randomization until death due to any 
cause (baseline to 5 years) 
Progression free surviv-
al 
(co-primary endpoint) 
 
PFS 
Time from randomization until date of objective disease 
progression (RECIST 1.1 assessed by BIRC and investiga-
tors) or death by any cause in the absence of progression 
(baseline to 5 years) 
Overall survival at 24 
months 
(secondary endpoint) 
OS24 
The number (%) of patients who are alive at 24 months 
after randomization per the Kaplan-Meier estimate of OS 
at 24 months (baseline to 5 years) 
Duration of response 
(secondary endpoint) 
DOR 
 
Time from date for first documented response of CR or PR 
until the first documented response of progression (BIRC- 
assessed RECIST 1.1) or death in the absence of progression 
(to 3 years) 
Objective response rate 
(secondary endpoint) ORR 
The number (%) of patients with at least one visit re-
sponse of CR or PR (BIRC-assessed RECIST 1.1 to 3 years) 
Proportion alive and 
progression free at 12 
months 
(secondary endpoint) 
APF12 
The number (%) of patients who are alive and progression 
free (BIRC-assessed RECIST 1.1 at 12 months after randomi-
zation per Kaplan-Meier estimate of PFS at 12 months to 3 
years) 
Proportion alive and 
progression free at 18 
months 
(secondary endpoint) 
APF18 
The number (%) of patients who are alive and progression 
free (BIRC-assessed RECIST 1.1 at 18 months after random-
ization per Kaplan-Meier estimate of PFS at 18 months to 3 
years) 
Time to death or distant 
metastasis  
(secondary endpoint) 
TTDM 
Any new lesion that is outside of the radiation field (BIRC-
assessed to 5 years) 
Safety, adverse events AE Incidence of adverse events and according to CTCAE 
(v4.03) 
Database lock Last verified June 2017  
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Title: Durvalumab after chemoradiotherapy in stage III NSCLC [3, 22] 
Study identifier NCT02125461, D4191C00001, EudraCT 2014-000336-42, PACIFIC 
Results and Analysis  
Analysis description Primary Analysis 
ITT: interim analysis of PFS was planned at approximately 367 events. At interim analysis, 371 pa-
tients had disease progression (214 durvalumab, 157 placebo), median follow-up of 14.5 months. At 
interim analysis, the HR for disease progression or death was estimated using Kaplan-Meier. Be-
tween-group comparisons were performed using log-rank test, stratified by age, sex, and smoking 
history. Sensitivity analyses included assessment of evaluation bias, evaluation-time bias, and attri-
tion bias in the determination of disease progression and adjustment for covariates in the estimat-
ing the HR for disease progression or death.   
A pre-planned analysis of PFS in 35 pre-specified subgroups was performed in which HR and 95% CI 
were calculated using an un-stratified Cox regression model. There was no multiplicity adjustment 
as the subgroup analysis was intended to show consistency of the treatment effect.  
Response rates were estimated using Clopper-Pearson and compared with Fisher’s exact test. Type I 
error was controlled for the co-primary endpoints and key secondary endpoint ORR, but not for 
other secondary endpoints. Efficacy was assessed in the ITT population, and safety was assessed in 
the as-treated population.  An external independent data and safety monitoring committee is as-
sessing safety in an ongoing analysis.  
Analysis population  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion 
 Age ≥18 years  
 Documented evidence of NSCLC (locally advanced, 
unresectable, stage III) 
 Patients must have received ≥2 cycles of platinum-
based chemotherapy concurrent with radiation ther-
apy 
 WHO Performance Status of 0 to 1 
 Estimated life expectancy of >12 weeks 
 
Exclusion 
 Prior exposure to any atni-PD-1 or anti-PD-L1 anti-
body 
 Active or prior autoimmune disease or history of im-
munodeficiency 
 Evidence of severe or uncontrolled systemic diseases, 
including active bleeding diatheses, or active infec-
tions including hepatitis B, C and HIV 
 Evidence of uncontrolled illness such as symptomatic 
congestive heart failure, uncontrolled hypertension or 
unstable angina pectoris 
 Any unresolved toxicity CTCAE > Grade 2 from the 
prior chemoradiation therapy 
 Active or prior documented inflammatory bowel dis-
ease (e.g. Crohn’s disease, ulcerative colitis) 
 
Characteristics 
 
Durvalumab 
(n = 476) 
Placebo 
(n = 237) 
Total 
(n = 713) 
Median age (range), years 
Age ≥65 years, n (%) 
64 (31–84) 
215 (45.2) 
64 (23–90) 
107 (45.1) 
64 (23–90) 
322 (45.2) 
Male sex, n (%) 334 (70.2) 166 (70.0) 500 (70.1) 
Race, n (%) 
Caucasian 
African American 
Asian 
Other 
NR 
 
337 (70.8) 
12 (2.5) 
120 (25.2) 
6 (1.3) 
1 (0.2) 
 
157 (66.2) 
2 (0.8) 
72 (30.4) 
6 (2.5) 
0 
 
494 (69.3) 
14 (2.0) 
192 (26.9) 
12 (1.68) 
1 (0.1) 
Disease stage, n (%) 
IIIA 
IIIB 
Other‡ 
 
252 (52.9) 
212 (44.5) 
12 (2.5) 
 
125 (52.7) 
107 (45.1) 
5 (2.1) 
 
377 (52.9) 
319 (44.7) 
17 (2.4) 
WHO performance score, n (%) 
0 
1 
NR 
 
234 (49.2) 
240 (50.4) 
2 (0.4) 
 
114 (48.1) 
122 (51.5) 
1 (0.4) 
 
348 (48.8) 
362 (50.8) 
3 (0.4) 
Tumour histology, n (%) 
Squamous 
Non-squamous 
 
224 (47.1) 
252 (52.9) 
 
102 (43.0) 
135 (57.0) 
 
326 (45.7) 
387 (54.3) 
PD-L1 status, n (%) 
TC <25% 
TC ≥25% 
Unknown 
 
187 (39.3) 
115 (24.2) 
174 (36.6) 
 
105 (44.3) 
44 (18.6) 
88 (37.1) 
 
292 (83.6) 
159 (42.8) 
262 (73.7) 
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Title: Durvalumab after chemoradiotherapy in stage III NSCLC [3, 22] 
Study identifier NCT02125461, D4191C00001, EudraCT 2014-000336-42, PACIFIC 
Analysis population 
(continuation) 
EGFR mutation status, n (%) 
Positive 
Negative 
Unknown 
 
29 (6.1) 
315 (66.2) 
132 (27.7) 
 
14 (5.9) 
165 (69.6) 
48 (24.5) 
 
43 (12.0) 
480 (135.8) 
180 (52.2) 
Smoking status, n (%) 
Current smoker 
Former smoker 
Never smoked 
 
79 (16.6) 
354 (74.4) 
43 (9.0) 
 
38 (16.0) 
178 (75.1) 
21 (8.9) 
 
117 (16.4) 
532 (74.6) 
64 (9.0) 
Previous radiotherapy, n (%) 
<54 Gy 
≥54 to ≤66 Gy 
>66 to ≤74 Gy 
>74 Gy 
Missing data 
 
3 (0.6) 
442 (92.9) 
30 (6.3) 
0 (0) 
1 (0.2) 
 
0 (0) 
217 (91.6) 
19 (8.0) 
0 (0) 
1 (0.4) 
 
3 (0.4) 
659 (92.4) 
49 (6.9) 
0 (0) 
2 (0.3) 
Previous chemotherapy, n (%) 
Adjuvant 
Induction 
Concurrent with radiation  
 
3 (0.6) 
123 (25.8) 
475 (99.8) 
 
1 (0.4) 
68 (28.7) 
236 (99.6) 
 
4 (0.6) 
191 (26.8) 
711 (99.7) 
Prior chemotherapy regimen, n 
(%) 
Cisplatin-based 
Carboplatin-based 
 
266 (55.9) 
199 (41.8) 
 
129 (54.4) 
102 (43.0) 
 
395 (55.4) 
301 (42.2) 
Best response to previous chemo-
radiotherapy, n (%) 
Complete response 
Partial response 
Stable response 
Progression 
Non-evaluable 
Non-applicable 
 
 
9 (1.9) 
232 (48.7) 
222 (46.6) 
2 (0.4) 
9 (1.9) 
2 (0.4) 
 
 
7 (3.0) 
111 (46.8) 
114 (48.1) 
0 (0) 
4 (1.7) 
1 (0.4) 
 
 
16 (2.2) 
343 (48.1) 
336 (47.1) 
2 (0.3) 
13 (1.8) 
3 (0.4) 
Abbreviations: APF12 = alive and progression free at 12 months; APF18 = alive and progression free at 18 months; BICR = blinded independent 
central review; CR = complete response; CTCAE = Common Terminology Criteria for Adverse Events; DOR = duration of response; EGFR = 
epidermal growth factor receptor; HR = hazard ratio; ITT = intent-to-treat; IV = intravenous; NR = not reported; NSCLC = non-small cell 
lung cancer; ORR = objective response rate; OS = overall survival; PD-L1 = programmed cell death ligand-1; PFS = progression free survival; 
PR = partial response; RECIST = Response evaluation Criteria in Solid Tumours; TC = tumour cell; TTMD = time to death or distant 
metastasis; WHO = World Health Organization, ‡Patients with other disease stages included 12 patients in the durvalumab group (4 with 
stage IV, 4 with stage IIB, 3 with stage IIA, and 1 with stage IA), and 4 patients in the placebo group (2 with stage IIB, 1 with stage IIA, 
and 2 with stage IB) 
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Table 5: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [28] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: block-randomised 2:1 durvalumab versus pla-
cebo via centralised interactive web-based and voice-based randomisation system; stratified by 
age (<65 vs ≥65 years) sex, and smoking history (current or former smoker vs never smoked) 
no 
Adequate allocation concealment: actual study drug given was determined by the centralised 
randomisation service that incorporates a standard procedure for generating randomisation; 
numbers; efforts made to minimise time between randomisation and starting study drug; 
unique code numbers matched kits used only once 
no 
Blinding 
Patient: blinded to study drug allocation; centralised randomisation. no 
Treating physician: placebo was identical in colour and the IV bags for ad-
ministration were identical in size; study drug was blinded using an opaque 
sleeve with tamper evident tape over the IV bag prior to dispensing; blinded 
to drug allocation except for pharmacist preparing study drug. 
no 
Outcome assessment: study centre staff blinded to study drug allocation; in-
vestigational centres will not have access to randomisation scheme until fi-
nal data analysis; pharmacists required to dispense study drug at study site; 
treatment codes kept within industry to safeguard integrity of the blind; 
IDMC will be provided with un-blinded data for their review. 
no 
Selective outcome reporting unlikely: with the exception of QoL, pharmacokinetic characteris-
tics, and immunogenicity, outcomes reported as specified in protocol; withdrawals and drop-
outs reported 
no 
No other aspects that increase the risk of bias: study designed by industry and academic advi-
sors; sponsor completed data analyses; authors had full access to the data; sponsor funded med-
ical writing  
yes 
Risk of bias – study level low 
Abbreviations: IDMC = independent data monitoring committee; QoL = quality of life 
 
 
 
